670 related articles for article (PubMed ID: 21714643)
1. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis.
van de Veerdonk FL; Plantinga TS; Hoischen A; Smeekens SP; Joosten LA; Gilissen C; Arts P; Rosentul DC; Carmichael AJ; Smits-van der Graaf CA; Kullberg BJ; van der Meer JW; Lilic D; Veltman JA; Netea MG
N Engl J Med; 2011 Jul; 365(1):54-61. PubMed ID: 21714643
[TBL] [Abstract][Full Text] [Related]
2. STAT1 hyperphosphorylation and defective IL12R/IL23R signaling underlie defective immunity in autosomal dominant chronic mucocutaneous candidiasis.
Smeekens SP; Plantinga TS; van de Veerdonk FL; Heinhuis B; Hoischen A; Joosten LA; Arkwright PD; Gennery A; Kullberg BJ; Veltman JA; Lilic D; van der Meer JW; Netea MG
PLoS One; 2011; 6(12):e29248. PubMed ID: 22195034
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for chronic mucocutaneous candidiasis.
van de Veerdonk FL; Netea MG
J Infect; 2016 Jul; 72 Suppl():S56-60. PubMed ID: 27161991
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune polyendocrinopathy candidiasis ectodermal dystrophy and other primary immunodeficiency diseases help to resolve the nature of protective immunity against chronic mucocutaneous candidiasis.
Kisand K; Peterson P
Curr Opin Pediatr; 2013 Dec; 25(6):715-21. PubMed ID: 24240291
[TBL] [Abstract][Full Text] [Related]
5. Two novel gain-of-function mutations of STAT1 responsible for chronic mucocutaneous candidiasis disease: impaired production of IL-17A and IL-22, and the presence of anti-IL-17F autoantibody.
Yamazaki Y; Yamada M; Kawai T; Morio T; Onodera M; Ueki M; Watanabe N; Takada H; Takezaki S; Chida N; Kobayashi I; Ariga T
J Immunol; 2014 Nov; 193(10):4880-7. PubMed ID: 25288569
[TBL] [Abstract][Full Text] [Related]
6. A novel gain-of-function STAT1 mutation resulting in basal phosphorylation of STAT1 and increased distal IFN-γ-mediated responses in chronic mucocutaneous candidiasis.
Martinez-Martinez L; Martinez-Saavedra MT; Fuentes-Prior P; Barnadas M; Rubiales MV; Noda J; Badell I; Rodríguez-Gallego C; de la Calle-Martin O
Mol Immunol; 2015 Dec; 68(2 Pt C):597-605. PubMed ID: 26514428
[TBL] [Abstract][Full Text] [Related]
7. Functional analysis of two STAT1 gain-of-function mutations in two Iranian families with autosomal dominant chronic mucocutaneous candidiasis.
Ostadi V; Sherkat R; Migaud M; Modaressadeghi SM; Casanova JL; Puel A; Nekooie-Marnany N; Ganjalikhani-Hakemi M
Med Mycol; 2021 Feb; 59(2):180-188. PubMed ID: 32526033
[TBL] [Abstract][Full Text] [Related]
8. Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.
Egri N; Esteve-Solé A; Deyà-Martínez À; Ortiz de Landazuri I; Vlagea A; García AP; Cardozo C; Garcia-Vidal C; Bartolomé CS; Español-Rego M; Yiyi L; Bosch-Amate X; Ferrando J; Yagüe J; Juan M; Alsina L
Allergol Immunopathol (Madr); 2021; 49(1):118-127. PubMed ID: 33528939
[TBL] [Abstract][Full Text] [Related]
9. Chronic mucocutaneous candidiasis due to gain-of-function mutation in STAT1.
Carey B; Lambourne J; Porter S; Hodgson T
Oral Dis; 2019 Apr; 25(3):684-692. PubMed ID: 29702748
[TBL] [Abstract][Full Text] [Related]
10. STAT1 Gain-of-Function and Dominant Negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC.
Hiller J; Hagl B; Effner R; Puel A; Schaller M; Mascher B; Eyerich S; Eyerich K; Jansson AF; Ring J; Casanova JL; Renner ED; Traidl-Hoffmann C
J Invest Dermatol; 2018 Mar; 138(3):711-714. PubMed ID: 29054602
[No Abstract] [Full Text] [Related]
11. Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy.
Ng WF; von Delwig A; Carmichael AJ; Arkwright PD; Abinun M; Cant AJ; Jolles S; Lilic D
J Allergy Clin Immunol; 2010 Nov; 126(5):1006-15, 1015.e1-4. PubMed ID: 20934207
[TBL] [Abstract][Full Text] [Related]
12. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC).
Zheng J; van de Veerdonk FL; Crossland KL; Smeekens SP; Chan CM; Al Shehri T; Abinun M; Gennery AR; Mann J; Lendrem DW; Netea MG; Rowan AD; Lilic D
Eur J Immunol; 2015 Oct; 45(10):2834-46. PubMed ID: 26255980
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors modulate innate immune responses to micro-organisms relevant to chronic mucocutaneous candidiasis.
Rösler B; Wang X; Keating ST; Joosten LAB; Netea MG; van de Veerdonk FL
Clin Exp Immunol; 2018 Nov; 194(2):205-219. PubMed ID: 30069986
[TBL] [Abstract][Full Text] [Related]
14. Mucocutaneous candidiasis and autoimmunity against cytokines in APECED and thymoma patients: clinical and pathogenetic implications.
Kisand K; Lilic D; Casanova JL; Peterson P; Meager A; Willcox N
Eur J Immunol; 2011 Jun; 41(6):1517-27. PubMed ID: 21574164
[TBL] [Abstract][Full Text] [Related]
15. Invariant natural killer T (iNKT) cell deficiency in chronic mucocutaneous candidiasis--a consequence or a cause?
Ng WF; Tudhope SJ; von Delwig A; Lilic D
Immunol Lett; 2011 Mar; 135(1-2):180-3. PubMed ID: 20923687
[TBL] [Abstract][Full Text] [Related]
16. [CMCD: Chronic Mucocutaneous Candidiasis Disease].
Okada S
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):109-117. PubMed ID: 28603201
[TBL] [Abstract][Full Text] [Related]
17. Chronic mucocutaneous candidiasis: characterization of a family with STAT-1 gain-of-function and development of an ex-vivo assay for Th17 deficiency of diagnostic utility.
Dhalla F; Fox H; Davenport EE; Sadler R; Anzilotti C; van Schouwenburg PA; Ferry B; Chapel H; Knight JC; Patel SY
Clin Exp Immunol; 2016 May; 184(2):216-27. PubMed ID: 26621323
[TBL] [Abstract][Full Text] [Related]
18. New host defense mechanisms against Candida species clarify the basis of clinical phenotypes.
Hanna S; Etzioni A
J Allergy Clin Immunol; 2011 Jun; 127(6):1433-7. PubMed ID: 21497889
[TBL] [Abstract][Full Text] [Related]
19. Chronic mucocutaneous candidiasis caused by a gain-of-function mutation in the STAT1 DNA-binding domain.
Takezaki S; Yamada M; Kato M; Park MJ; Maruyama K; Yamazaki Y; Chida N; Ohara O; Kobayashi I; Ariga T
J Immunol; 2012 Aug; 189(3):1521-6. PubMed ID: 22730530
[TBL] [Abstract][Full Text] [Related]
20. Ruxolitinib reverses dysregulated T helper cell responses and controls autoimmunity caused by a novel signal transducer and activator of transcription 1 (STAT1) gain-of-function mutation.
Weinacht KG; Charbonnier LM; Alroqi F; Plant A; Qiao Q; Wu H; Ma C; Torgerson TR; Rosenzweig SD; Fleisher TA; Notarangelo LD; Hanson IC; Forbes LR; Chatila TA
J Allergy Clin Immunol; 2017 May; 139(5):1629-1640.e2. PubMed ID: 28139313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
